Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0X7JR
|
|||
| Former ID |
DAP001349
|
|||
| Drug Name |
Eflornithine
|
|||
| Synonyms |
EFLORNITHINE; Ornidyl; 70052-12-9; 2-(Difluoromethyl)ornithine; alpha-Difluoromethylornithine; Difluromethylornithine; Eflornitina [Spanish]; Eflornithinum [Latin]; 2,5-diamino-2-(difluoromethyl)pentanoic acid; alpha-(Difluoromethyl)-DL-ornithine; N-Difluoromethylornithine; DFMO (growth regulator); 67037-37-0; Eflornithine [INN:BAN]; 2-(Difluoromethyl)-DL-ornithine; DL-alpha-(Difluoromethyl)ornithine; MDL 71782; CCRIS 3295; Ornithine, 2-(difluoromethyl)-; Eflornithinum; Eflornitina; DFMO hydrochloride; DFMO hydrochloride hydrate; EFLORNITHINE HYDROCHLORIDE; BMS 203522; Alpha-DFMO HCl; Alpha-Difluoromethylornithine; Alpha-Difluoromethylornithine hydrochloride; CPP-1X; Eflornithine (INN); Ornidyl (TN); DL-alpha-Difluoromethylornithine; DL-alpha-Difluoromethylornithine hydrochloride hydrate; D,L-alpha-Difluoromethylornithine; Alpha-(Difluoromethyl)-DL-ornithine; Alpha,delta-Diamino-alpha-(difluoromethyl)valeric acid; Ornithine, 2-(difluoromethyl)-, monohydrochloride; DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride; DL-Ornithine, 2-(difluoromethyl)-, monohydrochloride, monohydrate; 2,5-diamino-2-(difluoromethyl)pentanoic acid hydrochloride; 2-(Difluoromethyl)-DL-ornithine HCl; 2-(Difluoromethyl)-DL-ornithine hydrochloride; 2-(Difluoromethyl)-DL-ornithine monohydrochloride; 2-(Difluoromethyl)ornithine hydrochloride hydrate
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | African trypanosomiasis [ICD-11: 1F51; ICD-10: B56, B56.9; ICD-9: 86.5] | Approved | [1], [2] | |
| Trypanosomiasis [ICD-11: 1D51-1F53; ICD-9: 86.5] | Phase 2 | [3] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Sanofi-Aventis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C6H12F2N2O2
|
|||
| Canonical SMILES |
C(CC(C(F)F)(C(=O)O)N)CN
|
|||
| InChI |
1S/C6H12F2N2O2/c7-4(8)6(10,5(11)12)2-1-3-9/h4H,1-3,9-10H2,(H,11,12)
|
|||
| InChIKey |
VLCYCQAOQCDTCN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 70052-12-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
10198, 575150, 597889, 5340424, 7979149, 8151916, 15195195, 26697290, 29222157, 47736604, 48259361, 48413613, 48415938, 49857314, 50068858, 50111043, 57321552, 75030139, 90341137, 96024579, 103937549, 104302261, 123094710, 123121561, 124749707, 124879830, 125675814, 126666031, 126670951, 126685284, 129490554, 132563807, 134338563, 134339956, 135010753, 136342494, 137006071, 142212859, 162178731, 162221551, 162356694, 163134100, 164814590, 164823944, 171578146, 174006789, 178101866, 179117032, 184547857, 184605807
|
|||
| ChEBI ID |
CHEBI:41948
|
|||
| ADReCS Drug ID | BADD_D00751 ; BADD_D00752 | |||
| SuperDrug ATC ID |
D11AX16; P01CX03
|
|||
| SuperDrug CAS ID |
cas=070052129
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Ornithine decarboxylase (ODC1) | Target Info | Inhibitor | [4], [5] |
| BioCyc | Putrescine biosynthesis I | |||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | ||||
| Panther Pathway | Ornithine degradation | |||
| CCKR signaling map ST | ||||
| Pathwhiz Pathway | Spermidine and Spermine Biosynthesis | |||
| Pathway Interaction Database | Validated targets of C-MYC transcriptional activation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5176). | |||
| REF 2 | Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40. | |||
| REF 3 | ClinicalTrials.gov (NCT01636128) Urinary Biomarker Study With Sulindac and Difluoromethylornithine. U.S. National Institutes of Health. | |||
| REF 4 | Plasmodium falciparum and Plasmodium berghei: effects of ornithine decarboxylase inhibitors on erythrocytic schizogony. Exp Parasitol. 1987 Oct;64(2):237-43. | |||
| REF 5 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.